One of the oddities of the 2018 election cycle was that two incumbent congressmen ran for re-election while under felony indictment. One of the other oddities is that most of their constituents didn’t seem to mind.
Rep. Duncan D. Hunter (R-Calif.) won despite a fairly long list of charges, accused by prosecutors of misusing campaign contributions to pay for luxurious personal expenses. Last week, the Republican’s lawyers argued that the case against him is built on evidence from his campaign-finance forms, and according to Hunter’s legal team, those materials were filed as part of a legislative act and therefore should be immune from prosecutorial scrutiny.
I have a hunch this won’t work out especially well for the GOP lawmaker, but time will tell. Hunter’s trial is scheduled to begin in January. Several months later, he’ll likely face a primary challenge from former Rep. Darrell Issa (R-Calif.), who retired from a nearby district, and who’s apparently interested in a comeback.
And while there’s no doubt that Hunter’s scandal features all kinds of interesting drama, let’s not forget the other indicted congressman, who was in court yesterday. Roll Call reported:
Rep. Chris Collins pleaded not guilty to a revised indictment on Thursday in New York, where he, his son Cameron Collins and Stephen Zarsky, the father of Cameron Collins’ onetime fiancee, were initially indicted in August 2018 on insider trading charges and lying to the FBI.
Prosecutors have dropped three of the original eight securities fraud charges against Collins and two against his son and Zarsky in order to speed up the pretrial process in time for the trial slated for Feb. 3, 2020…. The defense team for Collins, a longtime Republican from New York’s 27th District, could delay that trial date for the congressman through a potentially lengthy pretrial appeals process.
For those who might need a refresher, the case against the New York Republican paints an unsettling picture.
Collins was a major investor in an Australian biomedical firm called Innate Immunotherapeutics — he also sat on the company’s board — while allegedly pushing legislation intended to benefit the company.
The Daily Beast reported last year that Collins has sponsored “several bills” that would have benefited Innate Immunotherapeutics, while also “trying to make changes to a government program that would save the company millions of dollars if its drug is approved by the FDA.”









